This is a really helpful reframing: APOE4 risk isn’t only about plaques, but it’s also about membrane biology! The way you connect overactive cPLA2 to a “leaky” lipid economy (liberating DHA/PUFAs from neuronal membranes, feeding downstream eicosanoid signaling, and sustaining inflammation) makes the story feel much more mechanistically actionable than the usual amyloid-only narrative. 
Two points I especially appreciated:
1. “Just take omega-3” may be too simplistic for APOE4. If APOE4 shifts fatty-acid handling toward higher turnover/oxidation or altered delivery to the CNS, then the bottleneck isn’t necessarily intake, but it’s where the DHA ends up and whether it stays incorporated where it matters (membranes). 
2. The idea (as you outline) that the brain may be pulling in DHA as compensation—not sufficiency—is a subtle but clinically important distinction, and it aligns with how fragile systems behave under chronic stress: higher flux can coexist with lower effective reserves. 
Also: spotlighting Hussein Yassine’s line of work helps anchor this in real translational science, especially the focus on APOE genotype, DHA delivery/uptake, and inflammatory lipid pathways. 
This post makes a strong case that membrane vulnerability + lipid signaling should be treated as a first-class target in APOE4, not an afterthought.
I really think we have a lot to learn and discuss about cPLA2 overactivity and what we can do in the meantime before folks like Yassine can develop inhibitors. This to me feels like THE cutting edge of the fight. I'm so glad you're here for it!
This is a really helpful reframing: APOE4 risk isn’t only about plaques, but it’s also about membrane biology! The way you connect overactive cPLA2 to a “leaky” lipid economy (liberating DHA/PUFAs from neuronal membranes, feeding downstream eicosanoid signaling, and sustaining inflammation) makes the story feel much more mechanistically actionable than the usual amyloid-only narrative. 
Two points I especially appreciated:
1. “Just take omega-3” may be too simplistic for APOE4. If APOE4 shifts fatty-acid handling toward higher turnover/oxidation or altered delivery to the CNS, then the bottleneck isn’t necessarily intake, but it’s where the DHA ends up and whether it stays incorporated where it matters (membranes). 
2. The idea (as you outline) that the brain may be pulling in DHA as compensation—not sufficiency—is a subtle but clinically important distinction, and it aligns with how fragile systems behave under chronic stress: higher flux can coexist with lower effective reserves. 
Also: spotlighting Hussein Yassine’s line of work helps anchor this in real translational science, especially the focus on APOE genotype, DHA delivery/uptake, and inflammatory lipid pathways. 
This post makes a strong case that membrane vulnerability + lipid signaling should be treated as a first-class target in APOE4, not an afterthought.
I really think we have a lot to learn and discuss about cPLA2 overactivity and what we can do in the meantime before folks like Yassine can develop inhibitors. This to me feels like THE cutting edge of the fight. I'm so glad you're here for it!